Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy
An Active Surveillance to Monitor the Real World Safety in Indian Patients Prescribed Nintedanib for the Treatment of Locally Advanced, Metastatic or Locally Recurrent Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Tumor Histology After First Line Chemotherapy
Sponsor: Boehringer Ingelheim
Listed as NCT03017885, this observational or N/A phase trial focuses on Non-small Cell Lung Cancer and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 58 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
58 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Apr 2024 — Jul 2024 [monthly]
Completed
-
Nov 2022 — Apr 2024 [monthly]
Completed
Status: Recruiting → Completed
-
Sep 2022 — Nov 2022 [monthly]
Recruiting
▶ Show 53 earlier versions
-
Jul 2022 — Sep 2022 [monthly]
Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Recruiting
-
May 2022 — Jun 2022 [monthly]
Recruiting
-
Apr 2022 — May 2022 [monthly]
Recruiting
-
Mar 2022 — Apr 2022 [monthly]
Recruiting
-
Feb 2022 — Mar 2022 [monthly]
Recruiting
-
Jan 2022 — Feb 2022 [monthly]
Recruiting
-
Dec 2021 — Jan 2022 [monthly]
Recruiting
-
Nov 2021 — Dec 2021 [monthly]
Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Recruiting
-
May 2021 — Jun 2021 [monthly]
Recruiting
-
Apr 2021 — May 2021 [monthly]
Recruiting
-
Mar 2021 — Apr 2021 [monthly]
Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Recruiting
-
Dec 2020 — Jan 2021 [monthly]
Recruiting
-
Nov 2020 — Dec 2020 [monthly]
Recruiting
-
Oct 2020 — Nov 2020 [monthly]
Recruiting
-
Sep 2020 — Oct 2020 [monthly]
Recruiting
-
Aug 2020 — Sep 2020 [monthly]
Recruiting
Status: Suspended → Recruiting
-
Jul 2020 — Aug 2020 [monthly]
Suspended
-
Jun 2020 — Jul 2020 [monthly]
Suspended
-
May 2020 — Jun 2020 [monthly]
Suspended
Status: Recruiting → Suspended
-
Apr 2020 — May 2020 [monthly]
Recruiting
-
Mar 2020 — Apr 2020 [monthly]
Recruiting
-
Feb 2020 — Mar 2020 [monthly]
Recruiting
-
Jan 2020 — Feb 2020 [monthly]
Recruiting
-
Dec 2019 — Jan 2020 [monthly]
Recruiting
-
Nov 2019 — Dec 2019 [monthly]
Recruiting
-
Oct 2019 — Nov 2019 [monthly]
Recruiting
-
Sep 2019 — Oct 2019 [monthly]
Recruiting
-
Aug 2019 — Sep 2019 [monthly]
Recruiting
-
Jul 2019 — Aug 2019 [monthly]
Recruiting
-
Jun 2019 — Jul 2019 [monthly]
Recruiting
-
May 2019 — Jun 2019 [monthly]
Recruiting
-
Apr 2019 — May 2019 [monthly]
Recruiting
-
Mar 2019 — Apr 2019 [monthly]
Recruiting
-
Feb 2019 — Mar 2019 [monthly]
Recruiting
-
Jan 2019 — Feb 2019 [monthly]
Recruiting
-
Dec 2018 — Jan 2019 [monthly]
Recruiting
-
Nov 2018 — Dec 2018 [monthly]
Recruiting
-
Oct 2018 — Nov 2018 [monthly]
Recruiting
-
Sep 2018 — Oct 2018 [monthly]
Recruiting
-
Aug 2018 — Sep 2018 [monthly]
Recruiting
-
Jul 2018 — Aug 2018 [monthly]
Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Oct 2017 — Apr 2018 [monthly]
Recruiting NA
-
Aug 2017 — Oct 2017 [monthly]
Recruiting NA
-
May 2017 — Aug 2017 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — May 2017 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .